A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy by Cocchio, Silvia et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=khvi20
Download by: [Universita di Padova] Date: 10 May 2016, At: 07:29
Human Vaccines & Immunotherapeutics
ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage: http://www.tandfonline.com/loi/khvi20
A postmarket safety comparison of 2 vaccination
strategies for measles, mumps, rubella and
varicella in Italy
Silvia Cocchio, Giovanna Zanoni, Roberta Opri, Francesca Russo, Vincenzo
Baldo & Collaborative group
To cite this article: Silvia Cocchio, Giovanna Zanoni, Roberta Opri, Francesca Russo, Vincenzo
Baldo & Collaborative group (2016) A postmarket safety comparison of 2 vaccination strategies
for measles, mumps, rubella and varicella in Italy, Human Vaccines & Immunotherapeutics,
12:3, 651-654, DOI: 10.1080/21645515.2015.1101198
To link to this article:  http://dx.doi.org/10.1080/21645515.2015.1101198
Accepted author version posted online: 03
Nov 2015.
Submit your article to this journal 
Article views: 108
View related articles 
View Crossmark data
SHORT REPORT
A postmarket safety comparison of 2 vaccination strategies for measles, mumps,
rubella and varicella in Italy
Silvia Cocchioa, Giovanna Zanonib, Roberta Opric, Francesca Russod, Vincenzo Baldoa, and Collaborative group#
aDepartment of Molecular Medicine, Public Health Section, University of Padua, Italy; bImmunology Unit, Policlinico G.B. Rossi, University Hospital,
Verona, Italy; cDepartment of Pathology and Diagnostics, Section of Immunology, University of Verona, Verona, Italy; dEuroHealth Net, Veneto Region
Health Directorate, Italy
ARTICLE HISTORY
Received 29 July 2015
Revised 8 September 2015
Accepted 24 September 2015
ABSTRACT
It is strategically important to monitor the safety proﬁle of vaccination schedules in order to achieve and
maintain high levels of coverage. We analyzed the cohort of individuals actively invited for measles,
mumps, rubella and varicella (MMRV) vaccination in the Veneto region (north-east Italy) from 8/1/2013 to
7/31/2014, assessing the onset of adverse events (AE) relating to 2 different vaccination strategies for
MMRV (MMRCV vs MMRV).
During the vaccination session at 14 months old, parents were given a form for recording local and
systemic reactions to vaccinations for 4 weeks afterwards. Overall, 12,288 forms were returned, and 84.6%
of them were included in this analysis (5,130 relating to MMRCV and 5,265 to MMRV); 37.3% of the sample
reported no AEs, with no difference between the 2 groups. Local reactions were more common in the
MMRCV group (9.6% vs 2.9%; RR 3.33; 95% CI 2.79–3.98), while there was no difference in general
reactions between the 2 groups (50% MMRCV vs 52% MMRV). The events most often reported were “fever
<39.5C,” which was more frequently associated with the MMRV strategy (p<0.001), and “skin blotches
and marks,” which occurred more often in the MMRCV group (p<0.001). Reports of “fever 39.5C” were
equally distributed between the 2 groups. Sixteen cases of febrile seizures were reported (0.14% in the
MMRCV group and 0.17% in the MMRV group).
Similar safety proﬁles were identiﬁed for the 2 vaccination strategies. Although the method used to
record reactions to vaccination demanded considerable resources, it enabled important information to be
collected on parents’ perception of the AEs occurring in response to their child’s vaccination.
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Attenuated viral vaccines against measles, mumps, rubella and
varicella have been associated with several adverse events,
including fever and febrile seizures.1-5 After the combined vac-
cine was licensed, the Advisory Committee on Immunization
Practices stated that the administration of separate measles,
mumps, rubella (MMR) and varicella (V) vaccines on the same
day was preferred for the ﬁrst recommended dose at 12 to
15 months of age (MMRCV).6,7
In 2005, as part of the Veneto Region’s routine childhood
immunization program, the chickenpox vaccine was offered to
children at 14 months of age, in co-administration with MMR,
with a second dose of varicella vaccine for 6-year-old children
and a catch-up dose for 12 year-olds with a negative history of
varicella (Regional Law No. 4403 of 30 December 2004).8
For the ﬁrst year of the vaccination program, the target was
to achieve a 60% adherence rate, given that the program began
with 2 separate MMR and varicella vaccines (the combined
MMRV vaccine became available in 2007); the adherence rate
was actually over 80%.9 New cases of varicella dropped from
about 61,000 in 2004 to 23,600 in 2008 and the hospitalization
rates decreased from 18.7/100,000 in 2000 to 0.8/100,000 in
2012.10
For combined MMRV vaccines, the most salient safety issue
emerging after their widespread use in routine practice was a
higher risk of febrile seizures. Analyses on post-marketing stud-
ies conducted on children receiving their ﬁrst dose of MMRV
vaccine have shown that they had febrile seizures more fre-
quently than children vaccinated with separate varicella and
MMR vaccines.11-13 As a result, the Veneto Regional Author-
ity’s recommendations left up to each local public health unit
to decide which strategy to use in relation to their local epide-
miological context.14
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In Italy the reporting of adverse events following immuniza-
tions (AEFIs) is regulated by a Ministerial Decree issued in
2003.15 and in the Veneto Region the Green Channel created
by the local public health authority is integrated with the
national surveillance system to offer advice on vaccinations at
risk of adverse events and to ensure an efﬁcient AEFI surveil-
lance system with regular feedback for vaccination personnel. 16
The present study analyses the adverse events (AEs)
recorded by means of an active surveillance comparing 2 alter-
native vaccination schedules (MMRV and MMRCV) in a sam-
ple of children in the Veneto Region, particularly focusing on
febrile seizures.
This observational prospective population-based cohort
study was conducted at 6 public health units in the Veneto
Region between 1st August 2013 and 31st July 2014. Written
informed consent was obtained from all children’s parents or
guardians before their inclusion in the study.
Children were eligible for the study if they were healthy at
the time of their ﬁrst vaccination against measles, mumps,
rubella and varicella. We included subjects given the combined
MMRV vaccine (Priorix-Tetra®, GlaxoSmithKline) or separate
MMR (Priorix®, GlaxoSmithKline or MMRVAXPRO®, Sanoﬁ
Pasteur MSD) and varicella (Varivax®, Sanoﬁ Pasteur MSD or
Varilrix®, GlaxoSmithKline) vaccines administered on the same
day as part of the routine childhood immunization program.
At the time of their children’s vaccination, parents/guardi-
ans were given a form and instructions on how to record local
and general symptoms solicited by the vaccinations, as well as
any other reactions. The ﬁrst section was completed by the
health service operator administering the vaccine, and con-
tained personal details and information on the type of vaccine
administered, the date of vaccination, the vaccine batch, and
the site and side of inoculation. The second section was for
parents to record any common reactions, distinguishing
between local (pain, swelling, redness, blisters) and systemic
events (fever, irritability, restlessness, drowsiness, blotches or
marks on the skin, swelling of the cheeks or ear, swollen lymph
glands in the neck, afebrile and febrile seizures, and so on), and
specifying the date of onset and duration. Parents were also
asked to record any allergic reactions occurring within 2 hours
from the inoculation (urticaria or others), any use of medica-
tion or resort to health care facilities, medical examinations or
laboratory tests. The forms were returned to the public health
unit a month later, at the child’s next vaccination appointment.
A standardized clinical and causality assessment framework
was applied to classify cases as deﬁnite, probable, possible,
unlikely, unrelated, or unclassiﬁable based on the data recorded
on the form.17 Subjects were kept under observation for
15 minutes after the vaccines were injected to check for any
immediate reactions, as conﬁrmed and recorded by healthcare
providers. Local reactions such as ecchymosis, erythema, indu-
ration, swelling and pain at the injection site, and systemic
reactions such as arthralgia, chills, fever, headache, malaise,
myalgia, fatigue and sweating were recorded on each subject’s
form for 7 d after vaccination. Then any moderate or serious
AEs occurring during the subsequent 4 weeks after vaccination
were recorded. During this observational period, any additional
vaccination was performed in accordance with the Veneto’s
vaccination schedule.
AEs rates were calculated per 100 vaccinations. Data were
analyzed using Epi Info TM 7.1.4.0 (Centers for Disease Control
and Prevention (CDC) Atlanta). The chi-square test and Stu-
dent’s t-test were conducted, and relative risks (RR) with bino-
mial 95% conﬁdence intervals (CI) were calculated to analyze
any differences between groups of subjects, as appropriate. A P
value < 0.05 was considered statistically signiﬁcant.
Data in the Local Health Authority registries are recorded
with the patient’s consent and can be used as aggregate data for
scientiﬁc studies without further authorization.18 This study
complies with the Declaration of Helsinki and with Italian pri-
vacy law.19
A total of 12,288 forms were returned during the study
period, but 1,893 (15.4%) were not included in this analysis
because the vaccines were not administered according to our
observational study inclusion criteria (1,397 received MMR
vaccine, alone or with other vaccines; 25 received MMRV with
other vaccines; and 471 received V, alone or with other vac-
cines). We thus assessed 10,395 subjects, 5,130 (49.4%) in the
MMRCV group and 5,265 (50.6%) in the MMRV group
(Fig. 1).
The children’s mean age at the time of their vaccination was
14.9§2.3 months (15.0§1.6 months in the MMRCV group,
and 14.9§2.7 months in the MMRV group); 51.2% of them
were male (50.7% and 51.7% in the MMRCV and MMRV
groups, respectively) and the majority (89.7%) were Caucasian.
There were no statistically signiﬁcant differences between the 2
groups’ demographic characteristics.
Overall, in 11,197 signs and symptoms solicited by the vacci-
nations were reported, and their frequency was similar in the 2
groups (53.3% in the MMRCV group versus 46.7% in the
MMRV group); 3,222 (28.8%) were considered unrelated to
vaccination (32.8% in the MMRCV group and 24.2% in the
MMRV group), with a RR of 1.53, and a 95% CI of 1.41–1.66.
The frequency of local reactions to vaccination was signiﬁ-
cantly lower at the site of injection for the MMRV than for the
MMR or varicella vaccines (p<0.01). In general, redness at the
injection site was the most frequently reported local reaction in
both groups.
Among the general symptoms solicited, fever (of any kind)
was the most often reported in both groups. A higher incidence
of any fever (deﬁned as an axillary temperature 37.5) was
observed in the MMRV group than in the MMRCV group
(44.3% vs. 31.6%; RR 1.72; 95% CI: 1.58–1.86). However, the
incidence of more severe fever (39.5C) did not differ statisti-
cally between the 2 groups, (4.7% after MMRV versus 3.9%
after MMRCV) (Table 1).
Some kind of rash was reported in 19.8% of subjects in the
MMRCV group and in 17.1% in the MMRV group (RR 1.19;
95% CI: 1.08–1.32). All adverse events regressed with no
sequelae, without any major medical interventions.
There were a total of 16 cases of febrile seizures (0.15%),
with no difference between the 2 groups (0.14% in the
MMRCV and 0.17% in the MMRV group). All subjects recov-
ered without sequelae.
At least one drug was administered to 18.6% of the children
(and the differences between the 2 groups were not statistically
signiﬁcant). In 87.5% of cases this involved paracetamol (55.1%
in the MMRV group vs 44.9% in the MMRCV group; RR 1.24;

























95% CI: 1.11–1.38). The family pediatrician was consulted for
2.8% of the children, 0.4% of them underwent laboratory tests,
0.9% were addressed to emergency services, and 0.2% were hos-
pitalized (again with differences between the 2 groups that were
not statistically signiﬁcant).
The Veneto Region is situated in the north-east of Italy
where the climate is generally temperate. The population of
4.8 million (9.2% children aged 0–9 years) accounts for 7.7% of
the Italian population.
In 2008 the Veneto Regional Authority abolished all manda-
tory vaccination and, in accordance with legislation suspending
mandatory vaccination, it has since undertaken speciﬁc proj-
ects, including ad hoc software for managing vaccinations, pre-
vaccination counseling, adverse event surveillance, training for
healthcare workers, the surveillance of vaccine-related disor-
ders, the promotion of healthcare in the ﬁrst years of life, and
the surveillance and prevention of diseases related to travel and
immigration. The Veneto’s vaccine coverage data reveal a
decline in immunization coverage rates for all vaccinations,20
though levels remain above the goal of 95% set by the Italian
National Immunization Plan21 (a general decrease has also
recently been observed in Italy as a whole).22
This observational cohort study compared the safety of the
ﬁrst dose of MMRV vaccine with that of the MMRCV co-
administration in children from the Veneto region. Overall,
our study showed that both vaccination strategies are safe and
well-tolerated. The method used to actively collect the child-
ren’s reactions to vaccination demanded considerable resour-
ces, but generated useful information on how parents perceive
any vaccination-related adverse events. After applying a causal
relationship, the number of related AEs dropped signiﬁcantly
in the MMRCV group, conﬁrming that performing more injec-
tions increases parents’ anxiety because of the perceived addi-
tional pain for the infant.23 A higher incidence of fever was
observed in the MMRV group than after MMRCV, but this
only applied to mild fever, while there was no difference
between the 2 groups for severe fever (39.5C axillary temper-
ature). These results are comparable with a recent meta-analy-
sis reporting higher frequencies of fever associated with
MMRV.24 This observation is also compatible with the fever
peak described after the administration of other vaccines
containing measles strains.13
Due to the few episodes of febrile seizures in our sample, our
analyses were of limited power for the purpose of assessing the RR
Table 1. Numbers and rates of adverse events reported by vaccination group and
type of reaction.
MMRCV (nD5,130) MMRV (nD5,265)
n (%) n (%) RR (95% CI)
Local reaction 490 (9.6) 151 (2.9) 3.33 (2.79–3.98)
pain 87 (1.7) 39 (0.7) 2.31 (1.58–3.38)
swelling 155 (3.0) 47 (0.9) 3.38 (2.45–4.68)
redness 296 (5.8) 62 (1.2) 4.89 (3.73–6.42)
blisters 64 (1.2) 17 (0.3) 3.90 (2.28–6.66)
Systemic reaction 2,567 (50.0) 2,736 (52.0) 0.96 (0.92–1.00)
fever 39.4C 1,421 (27.7) 2,086 (39.6) 0.58 (0.54–0.63)
fever 39.5C 199 (3.9) 245 (4.7) 0.80 (0.69–1.00)
irritability 655 (12.8) 497 (9.4) 1.35 (1.21–1.51)
skin blotches
and marks
1,016 (19.8) 901 (17.1) 1.16 (1.07–1.26)
parotid swelling 37 (0.7) 22 (0.4) 1.73 (1.02–2.92)
arthralgia 55 (1.1) 31 (0.6) 1.82 (1.17–2.82)
febrile seizures 7 (0.14) 9 (0.17) 0.80 (0.30–2.15)
no febrile seizures 2 (0.04) 1 (0.02) 2.05 (0.18–22.6)
unrelated reaction 690 (13.5) 520 (9.9) 1.36 (1.22–1.52)
no reaction reported 1,869 (36.4) 2,009 (38.2) 0.95 (0.91–1.00)
p < 0.05
Figure 1. Study ﬂow-chart.

























of seizures after MMRV vis-a-vis MMRCV. The overall incidence
recorded in our analysis was similar to that of another observa-
tional study,13 but our data derive from an active surveillance that
might increase the frequency of AEs reporting. It is also important
to correct the denominator (total number of subjects vaccinated in
each of the 2 groups), which is found to be underestimated because
parents whose children experience no AEs are less likely to com-
plete and return the form.
This analysis reveals similar safety proﬁles for the 2 vaccina-
tion strategies; an in-depth analysis is needed to evaluate the
possible causal relationship between some adverse events
reported with incomplete information and vaccination.
The greater risk of febrile seizures with combined quadrivalent
vaccines has to be balanced against the potential advantage of a
single injection in terms of improving varicella immunization cov-
erage rates.25 This beneﬁt might be important in our present set-
ting, which shows a general decline in vaccination coverage.
In conclusion, our data suggest good safety proﬁles for both
vaccination strategies after the ﬁrst dose. Healthcare providers
should analyze the risks and beneﬁts after providing adequate
counseling for guardians before they choose a vaccination strat-
egy. Although the method used to actively record any reactions
to vaccination demanded considerable resources, it enabled us
to collect important information on the parents’ perception of
the AEs occurring in response to their child’s vaccination.
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